Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Active, not recruiting · NCT04447651 · Registry updated 2026-07-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Not stated | 2026-07-21 | NCT04447651 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Avon Breast Health Access Fund | 1 |
| Bristol-Myers Squibb | 422 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
| Vanderbilt University | 62 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins University | Baltimore | United States | 1 |